Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery

B. Zimmer · G. Pallocca · N. Dreser · S. Foerster · T. Waldmann · J. Westerhout · S. Julien · K. H. Krause · C. van Thriel · J. G. Hengstler · A. Sachinidis · S. Bosgra · M. Leist

Abstract  Developmental toxicity in vitro assays have hitherto been established as stand-alone systems, based on a limited number of toxicants. Within the embryonic stem cell-based novel alternative tests project, we developed a test battery framework that allows inclusion of any developmental toxicity assay and that explores the responses of such test systems to a wide range of drug-like compounds. We selected 28 compounds, including several biologics (e.g., erythropoietin), classical pharmaceuticals (e.g., roflumilast) and also six environmental toxicants. The chemical, toxicological and clinical data of this screen library were compiled. In order to determine a non-cytotoxic concentration range, cytotoxicity data were obtained for all compounds from HEK293 cells and from murine embryonic stem cells. Moreover, an estimate of relevant exposures was provided by literature data mining. To evaluate feasibility of the suggested test framework, we selected a well-characterized assay that evaluates ‘migration inhibition of neural crest cells.’ Screening at the highest non-cytotoxic concentration resulted in 11 hits (e.g., geldanamycin, abiraterone, gefitinib, chlorpromazine, cyproconazole, arsenite). These were confirmed in concentration–response studies. Subsequent pharmacokinetic modeling indicated that triadimefon exerted its effects at concentrations relevant to the in vivo situation, and also interferon-β and polybrominated diphenyl ether showed effects within the same order of magnitude of concentrations that may be reached in humans. In

B. Zimmer and G. Pallocca have contributed equally to this work.

Electronic supplementary material  The online version of this article (doi:10.1007/s00204-014-1231-9) contains supplementary material, which is available to authorized users.

B. Zimmer
Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Research, New York City, NY, USA

B. Zimmer
Developmental Biology Program, Sloan-Kettering Institute, New York City, NY, USA

G. Pallocca · N. Dreser · S. Foerster · T. Waldmann · M. Leist
Department of Biology, University of Konstanz, 78457 Constance, Germany

G. Pallocca (✉)
Doerenkamp-Zbinden Chair for In Vitro Toxicology and Biomedicine, University of Konstanz, Box 657, Universitätsstr. 10, 78457 Constance, Germany
e-mail: giorgia.pallocca@uni-konstanz.de

J. Westerhout · S. Bosgra
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek (TNO), 2628 VK Delft, The Netherlands

S. Julien · K. H. Krause
Department of Pathology and Immunology, Geneva Medical Faculty, University of Geneva, 1211 Geneva, Switzerland

C. van Thriel · J. G. Hengstler
Leibniz Research Centre for Working Environment and Human Factors (IfADo), Technical University of Dortmund, 44139 Dortmund, Germany

A. Sachinidis
Center of Physiology and Pathophysiology, Institute of Neurophysiology, University of Cologne, 50931 Cologne, Germany

© The Author(s) 2014. This article is published with open access at Springerlink.com
conclusion, the test battery framework can identify compounds that disturb processes relevant for human development and therefore may represent developmental toxicants. The open structure of the strategy allows rich information to be generated on both the underlying library, and on any contributing assay.

**Keywords**  Test battery-based compound screening · Developmental toxicity testing · hES-induced pluripotent stem cell (hiPSC) system · Neural crest migration assay

**Abbreviations**

ADME  Absorption, distribution, metabolism, excretion  
bFGF  Basic fibroblast growth factor  
BMC  Benchmark concentration  
BMCL  Benchmark concentration 95 % confidential interval lower limit  
CC  Clinical concentration  
CCR  Chemokine receptors  
CNS  Central nervous system  
CSF  Cerebrospinal fluid  
CYP  Cytochrome P450  
DLL  Distal less  
DNT  Developmental neurotoxicity  
DT  Developmental toxicity  
EGF  Epidermal growth factor  
ESNATS  Embryonic stem cell-based novel alternative tests  
FCC  Free concentration  
GD  Gestational day  
HEK293  Human embryonic kidney 293 cell  
hESC  Human embryonic stem cell  
IFN-β  Interferon β  
LOAEC  Lowest observed adverse effect concentration  
MEF  Mouse embryonic fibroblast cell  
mESCN  Murine embryonic stem cell-derived neural precursor  
MINC  Migration of neural crest cell  
MPP  Matrix metalloproteinases  
NCC  Neural crest cell  
NOAEL  No observed adverse effect level  
PBDE  Polychlorinated biphenyl  
PBPK  Pharmacokinetic  
PCB  Polychlorinated biphenyl  
ROI  Region of interest

**Introduction**

Individual human embryonic stem cell-based development toxicity test systems have been established by several laboratories (Jagtap et al. 2011; Balmer et al. 2012; Stummann et al. 2009). A next step will be the combination of these and other assays to a comprehensive battery able to predict human developmental toxicities (Leist et al. 2012b; van Thriel et al. 2012). Cultures of differentiating pluripotent stem cells such as human embryonic stem cells (hESC) or human-induced pluripotent stem cells (Leist et al. 2008a; Thomson et al. 1998; Takahashi et al. 2007) offer unique possibilities of studying the very early steps of human development that lead to the formation of germ layers and primordial tissues. This opportunity was seized by the European Union research consortium for the use of ‘embryonic stem cell-based novel alternative tests’ (ESNATS) for the prediction of toxicity of drug candidates (www.esnats.eu). This project focused on the one hand on transcriptomics-based toxicity predictions (Krug et al. 2013b; Kuegler et al. 2010). On the other hand, several tests were established, which allowed the assessment of neurochemical and cell biological cell functions (Stiegler et al. 2011; Zimmer et al. 2011b; 2012; Krug et al. 2013a) and of complex cell interactions (Preynat-Seauve et al. 2009; Kuegler et al. 2012). Moreover, concepts have been developed to compare relevant in vitro and in vivo concentrations (Bosgra et al. 2012; Krug et al. 2013a; Zimmer et al. 2011a), and to incorporate systems for metabolic activation of drugs (Godoy et al. 2013). It is assumed by many experts that the combination of such different tests in a battery may eventually be able to predict human developmental toxicity (Basketter et al. 2012; Piersma et al. 2013; Schenk et al. 2010). The hESC-based test systems of ESNATS cover different aspects of development. For instance, the UKK system (Meganathan et al. 2012) models early multi-germ-layer differentiation, while the UKN1 system (Balmer et al. 2012) models specific neuroectodermal differentiation. The UKN2 system, also known as ‘migration inhibition of neural crest’ assay (MINC) (Zimmer et al. 2012) is a functional test probing the inhibition of neural crest cell migration by chemicals. During the initial establishment of the assays, only a small number of positive and negative controls were tested. Therefore, the applicability domain of these assays and their response dynamics when faced with a broader variety of compounds are unknown. Moreover, the information from only few compounds is not sufficient to evaluate how far the test systems are complementary, and where they may be redundant in the information they provide.

In DNT test library selection, new approaches are required (Leist et al. 2012a) to break a vicious circle between lack of sufficient tool compounds, and the inability to classically validate test systems without such compounds (Leist et al. 2010, 2012b). One of these would be a screening approach of hitherto little characterized compounds in multiple test systems. This would provide information on which biological processes may be targeted by the compounds. Together with mechanistic studies on the mode of action, this approach may allow to build a case for...
a hazard estimate independent of correlations with in vivo data (Kadereit et al. 2012). Moreover, characterization of the available assays would be promoted.

For the design of such a battery of different tests, experience from earlier approaches can be used as guidance. Test batteries may for instance be constructed in a tiered way to avoid redundant testing. If information on each compound from every test is desired, then non-tiered approaches are more useful. Examples from the field of reproductive toxicity testing are for instance the ReProTect feasibility study (Schenk et al. 2010) or the ChemScreen test battery (Piersma et al. 2013). Non-tiered testing is also performed in the ToxCast Program, in which hundreds of tests have been run in parallel, to use the data afterward—in combination with pre-existing in vivo data—for predictions of drivers and mechanisms of reproductive toxicity (Kleinsteuer et al. 2011; Padilla et al. 2012; Sipes et al. 2011).

Here, we defined a framework for a test battery, and we provided an initial characterization of a core set of test compounds which can be expanded at later stages. To evaluate the feasibility of the suggested framework and the usefulness of the set of compounds, we selected one well-characterized assay for a first screen. The MINC assay (Zimmer et al. 2012) was selected, as it is based on a functional endpoint, and it affords sufficient throughput to evaluate a compound battery of that size. The underlying biological rationale of the test is that disturbance of neural crest migration by toxicants leads to severe malformations in different species. Several factors (e.g., genetics and chemicals) have already been identified as causes for neural crest (NC)-related developmental defects (Di Renzo et al. 2007; Fuller et al. 2002; Menegola et al. 2000). Identification of several hits in such a functional assay provides a good starting point for future characterization of the compounds by more phenotypic assays and for correlations of functional disturbances with, e.g., transcriptome changes.

Materials and methods

Cell culture

The reporter hES cell line H9-Dll1 (GFP under Dll1 promoter) was provided by Mark Tomishima from the Memorial Sloan-Kettering Cancer Centre (MSKCC, NY, USA). Import of the cells and all experiments were carried out according to German legislation under the license number 1710-79-11-3-27 of the Robert-Koch Institute. H9-Dll1 cells were maintained on Mouse Embryonic Fibroblasts (MEFs) in DMEM/F12 (Gibco) medium containing 20 % of serum replacement, HEPEES (1 M, Gibco), l-glutamine (Glutamax, Gibco), non-essential amino acids (MEM NEAA, Gibco), beta-mercaptoethanol (Gibco) and basic fibroblast growth factor (10 ng/ml, Invitrogen). The murine ES cell line CGR8 was obtained from the European Collection of Cell Culture (ECACC, UK). CGR8 cells were maintained on 0.1 % gelatin-coated dishes in BHK21 medium, supplemented with 10 % fetal calf serum, l-glutamine, non-essential amino acids, penicillin/streptomycin and leukemia inhibitory factor (Kern et al. 2013). HEK293 (CRL-1573, ATCC) cell line was maintained in DMEM supplemented with 10 % fetal calf serum at 37 °C in a humidified atmosphere containing 5 % CO₂.

Neural differentiation protocols

The mESC cell line (CGR8) was differentiated toward a neural stem cell phenotype using the protocol described by Barberi et al. (2003). Briefly, CGR8 were seeded on irradiated MS5 cells and cultivated in DMEM medium containing 15 % Knock-out Serum Replacement, non-essential amino acids, beta-mercaptoethanol and penicillin/streptomycin. After 4 days, cells were replated on polyornithine (15 μg/ml)-coated dishes in N2 medium containing DMEM, N2 supplement, penicillin/streptomycin and 10 ng/ml of basic human fibroblast growth factor (Invitrogen). Differentiation of hESC into neural crest cells was initiated on Mitomycin C-treated murine bone marrow-derived stromal MS5 cell line and continued as described in Zimmer et al. (2012).

Evaluation of a non-cytotoxic range by resazurin assay and benchmark concentration (BMC) calculation

The effects of the toxic compounds on cell viability of two cell lines were evaluated by using the resazurin assay. The assay is based on the capability of viable and healthy cells to reduce resazurin to resorufin, which can be measured by a colorimetric or fluorimetric shift as described earlier (Zimmer et al. 2012). HEK293 cells and mESC-derived neural stem cells (mESCh) were exposed for 48 h to the different substances. mESCh were exposed to test compounds after 6 days of differentiation. After this period, the cells were incubated at 37 °C and 5 % CO₂ with 10 μg/ml resazurin for 30 min (HEK293) or up to 5 h (neural stem cells). The background fluorescence of resazurin itself was determined by including a resazurin only control. Resazurin reduction was analyzed in cell culture medium fluorimetrically (λex = 530 nm, λem = 590 nm). These data were used to model a concentration–response curve and to calculate the concentration corresponding to a 10 % reduction in viability (BMC10). In addition, the BMC15 and the lower limit of its 95 % CI (BMCL15) were determined. This latter value was used as estimate for the upper boundary of the non-cytotoxic concentration range.
Cell migration analysis

Cell migration analysis was carried out using a scratch assay design as described in Lee et al. (2009) and Zimmer et al. (2012) with minor modifications. hESC-derived NCCs were grown to a confluent monolayer using 48-well plates (Corning). Right before starting the assay, each well was scratched using a 20-μl pipette tip in order to create a cell-free gap. The medium was removed and replaced by fresh medium containing the test chemicals. The width of the cell-free gap was determined right after scratching in a control plate in order to define the dimension of the region of interest (ROI) for the analysis. The cells were exposed to the toxicants for 48 h; after this period, the general cytotoxicity was assessed by the resazurin reduction assay. Migration of NCC was evaluated by fluorescence microscopy analysis. In order to easily count the number of cells, incubation with fresh medium containing the DNA dye H-33342 (1 μg/ml) was performed for 30 min. After the incubation period, random images along the scratch were taken at 4× magnification. The number of cells with H-33342-positive nuclei within the ROI was automatically calculated by the use of a KNIME flowchart.

Chemical exposure during migration

hESC-derived neural crest cells were exposed to chemicals in N2 medium containing EGF (20 ng/ml) and FGF2 (20 ng/ml). For a detailed list of chemicals and their tested concentration range used in this study, see Fig. 3 and Fig. S1, S2.

In vitro: in vivo comparison of toxicity data by PBPK modeling

In order to evaluate the clinical relevance of the in vitro concentrations found to impair the migration of the hESC-derived NCCs in this study, a three-step (physiology-based) pharmacokinetic (PBPK) modeling strategy has been used, as already described in Krug et al. (2013b) and Piersma et al. (2013). Briefly, the following steps were taken: (a) choice of an appropriate absorption, distribution, metabolism, excretion (ADME) model; (b) use of this model to simulate plasma and/or target tissue concentrations in time corresponding to the exposure (dose, route of administration, interval) at which relevant toxic effects were observed in already published in vivo studies; (c) calculation of the nominal concentration in vitro that has the same unbound concentration as the toxic concentration in vivo (when possible).

In vitro: in vivo comparison of toxicity data for interferon β

A PBPK model for the analysis of interferon β (IFN-β) kinetics in monkeys, described by Mager et al. (2003), was implemented in the acslX software (version 3.0.2.1, Aegis Technologies) (step a). The original model was built on the basis of data from 18 cynomolgus monkeys that were exposed i.v. to single doses of 1, 3, 10 MIU/kg and then to a s.c dose of 0.3 ml/kg of IFN-β. In vivo developmental toxicity concentrations of the drug have been extrapolated from a study reporting the effects of the exposure of IFN-β in pregnant cynomolgus monkeys (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDeveloptedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm106138.pdf) (step b).

In vitro: in vivo comparison of toxicity data for triadimefon

A PBPK model for the pesticide triadimefon and its metabolite triadimenol in rats published by Crowell et al. (2011) was reconstructed in acslX and used to predict the target tissue concentration related to the exposure scenarios leading to toxic effects on male fertility and CNS toxicity (step a). Developmental toxicity-inducing concentrations were extrapolated from the in vivo study by Goetz et al. (2007), in which pregnant rats have been exposed to the pesticide. Two exposure scenarios were simulated: Dietary exposure assuming a constant intake of the entire drug dose within the first 12 h of 24-h periods; oral gavage, modeled as a bolus dose into the liver compartment (step b). The nominal in vitro concentrations equivalent to the concentrations predicted in vivo were determined correcting for the differences in albumin concentration and lipid fraction between plasma or cerebrospinal fluid and test medium, using the follow equations:

$$EC_x = EC_p \times \left\{ \frac{(1 - f_{p,b}) \times \left( 1 + K_{ow} \times VFL_p \right)}{1 + K_{ow} \times VFL_p + f_{p,b} \times \frac{P_x}{P_p}} \right\}$$

$$EC_{u,x} = \frac{EC_x - \frac{P_x}{P_p} \times f_{p,b} \times EC_p}{1 + K_{ow} \times VFL_p}$$

where EC represents the effective concentration; f_{p,b} the plasma fraction unbound; K_{ow} the octanol:water partition coefficient; VFL the lipid fraction; P the albumin concentration; suffix u means unbound; suffix p the plasma; and suffix x the other medium (in vitro or CSF) (step c).

The parameters of free (unbound) fraction, octanol:water partition and blood:plasma concentration ratio were taken from the published study by (US EPA 2006) and 0.11, 912 and 0.84, respectively. Data for rat CSF (estimated as 0.5 % of plasma) were taken from (Habgood et al. 1992; Koch et al. 2001) and data for MINC culture medium were calculated based on information provided by the supplier.
A PBPK model was constructed based on data of tissue distribution, metabolism and excretion of PBDE-99 as described by Hakk et al. (2002) and Chen et al. (2006) (step a). The PBPK model structure to describe the kinetics of PBDE-99 is shown in Fig. S4a. The model contains a gastrointestinal lumen compartment (GI), two rapid equilibrium compartments (T1 and T2), a blood compartment (B), a lipophilic tissues compartment (F) representing adipose tissue and skin, and compartments for urinary and fecal excretion (Ur and Fe). The exchange between blood and tissue compartments is described by first-order rate constants k_{b1}, k_{1b}, k_{b2}, k_{2b}, k_{bf} and k_{fb} with unit h^{-1}. The compound is absorbed into T1—containing intestinal tissues and liver, but not further specified—by a rate k_{a}, and eliminated back into GI with rate k_{e}. Excretion occurs from the blood compartment with rate k_{ur} and from the GI compartment with rate k_{e}. The model was described as a set of differential equations in acslX. Concentrations were calculated from amounts by dividing compartment volumes: 0.21, 0.56 and 0.06 ml/g BW (body weight) for lipophilic tissues, rapid equilibrium tissues and blood, respectively, as reported by Brown et al. (1997). The estimated parameter values are listed in the supplemental material (Fig. S3b). The model performance was demonstrated by comparison of model predictions to in vivo PK data reported by Chen et al. (2006) for a single oral dose of 1 μmol/kg (Fig. S3 c,d) and an intravenous bolus dose of 1 μmol/kg (Fig. S3e, f). In vivo developmental toxicity concentrations were extrapolated by the data from Kuriyama et al. (2005) and Viberg et al. (2005), where neuro-developmental effects are observed in rats exposed to PBDE-99, during the gestational or the early infancy period (step b).

Statistics and data mining

For the resazurin assay, five technical replicates for HEK293 cells and four biological replicates for mESCN cells have been analyzed for each compound and concentration. For the migration assay, the number of migrated cells was automatically counted in ≥4 different images per experiment by a KNIME flowchart-based software. All data displayed are means from three independent biological experiments. Each biological experiment consisted of at least four technical replicates. Statistical differences were tested with GraphPad Prism 5.0 (Graphpad Software, La Jolla, USA) by applying ANOVA using Bonferroni’s post hoc test. Independent biological experiments (not technical replicates) were the basic unit used for statistical testing.

### Results

Several murine and human stem cell-based developmental toxicity test systems have been developed by ESNATS project partners (Balmer et al. 2012; Krug et al. 2013b; Stiegler et al. 2011; Zimmer et al. 2012; Kern et al. 2013; Jagtap et al. 2011) and others (Fritzsche et al. 2011; Seiler and Spielmann 2011; Hogberg et al. 2010; Pallocca et al. 2013; Piersma et al. 2013; Suzuki et al. 2011). All these assays have been evaluated individually with positive and negative control compounds regarding their biological relevance for fundamental processes of mammalian development. However, little is known how such test systems can be combined to yield information on drug toxicity.

Important features of the test battery framework are the characterization of the compounds concerning general cytotoxicity, relevant in vivo concentrations and other necessary background data. Accessory modules for hit follow-up and in vitro–in vivo extrapolation should provide rich information on many of the compounds in the future. In fact, one of the initial purposes of the test battery was the pre-filtering of hits for further toxicogenomics follow-up, for instance by transcriptome profiling (Figs. 1, 2a). This will be performed, once a sufficient number of hits will be characterized in different assays.

### Selection of test battery compounds

The 28 compounds were compiled according to the selection criteria outlined in Fig. 2b. The test library reflects a compromise between the different criteria. Our choice marks a deliberate and intentional departure from the use of known toxicants and endpoint-specific controls (reviewed in Kadereit et al. 2012; Crofton et al. 2011; Leist et al. 2010), and it puts emphasis on the exploration of unknown drugs. Besides the drugs, a small selection (six substances) of environmental pollutants (e.g., PCB, PBDE, arsenic) was included as likely positive controls for many test systems. The group of drugs also included biologics (e.g., interferon-β, oxytocin) and peptide-related small molecules (e.g., sitagliptin, galnon). Some of the biologics were included as they are known to cross the blood brain barrier in vivo (e.g., G-CSF, erythropoietin). Finally, three compounds (sulfadiazine, chlorpromazine, amiodarone) were chosen because another drug screen (Kern et al. 2013) suggested a potential for developmental neurotoxicity. For all compounds of the test library, essential chemical and pharmacological information was compiled (Fig. S1, S2; Fig. 3). For environmental compounds with known neurotoxicity (developmental neurotoxicity) we referred to several pertinent in vivo and in vitro studies.
Pre-screening of test battery compounds for general cytotoxicity

Most developmental neurotoxicity assays give reliable and specific results only when compounds are used at concentrations that do not trigger general cytotoxicity/cell death. This range has to be determined for each compound and each test system. However, most available assays allow only a relatively low throughput of samples. Therefore, it would be more efficient and economical to get some rough initial information on non-cytotoxic concentration ranges before the onset of testing. For this purpose, we used two different assays. The first was based on human HeK293 cells. Resazurin reduction was applied as viability endpoint after exposure to the test battery compounds for 48 h. The second assay made use of mESCn differentiated toward neural lineage. Also here, viability of the cells was determined by resazurin reduction after a 48 h exposure period during the initial stages of differentiation (starting on day 6). The combination of these assays was meant to cover many modes-of-action of cytotoxicants across species and cell biological functions.

To determine the non-cytotoxic concentration range, compounds were tested at multiple concentrations. We then used a mathematical procedure to determine a benchmark concentration as upper limit of the non-cytotoxic range. The procedure is displayed in detail for the example compound geldanamycin (Fig. 4). For practical purposes, we used the real data point closest to this calculated theoretical threshold as toxicity threshold (Fig. 3). In most cases (16 compounds) in which comparative data were available, minimum cytotoxic concentrations of the compounds for the two cell types were similar (<5-fold difference). For all remaining substances (8 compounds), the embryonic stem cell system showed a higher sensitivity than the HeK293 cell line (Fig. 3). Cytokines were only tested at

---

**Fig. 2** Test battery design criteria
pharmacological concentrations to be expected in body fluids, and they all proved to be non-cytotoxic at these test concentrations (Fig. 3). In summary, the viability data give a rough indication on good starting points, but more precise data are needed for each new experimental model and for each experimental variation within a given test system (see below).

**Determination of toxicologically relevant concentration ranges**

Besides non-cytotoxicity, further criteria are important to determine reasonable test concentrations and to interpret the data. To allow decisions on concentration ranges (e.g., for cytokines) and interpretation of screen results, we compiled the clinical blood and tissue concentrations (CC) for most compounds. These, together with data on plasma protein binding, were used to calculate the free plasma concentrations in patients. The latter data are important to relate in vivo data to in vitro concentrations. While an overview of the data is given in Fig. 3, more detailed information has been compiled in a supplementary table (Fig. S4).

For extrapolation of in vivo data to in vitro concentrations, often the issue arises, whether $C_{\text{max}}$ (the peak concentration reached in clinics) or AUC (the average concentration found in a patient) should be used as anchor point for calculations. In the present study, both plasma peak ($C_{\text{max}}$) and average data were considered. This allows case-by-case decisions, depending on the assumed mechanism of toxicity. For instance, it may be plausible that cytokine receptors need to be triggered only for a short time (by $C_{\text{max}}$) to generate intracellular signals that potentially affect differentiation. In contrast to this situation, continuous cytokine signaling (in the AUC range) may be required to alter the cellular

### Table 1: Clinical Blood and Tissue Concentrations (CC)

| Compound | Solvent | Clinical conc. | Free conc. | Highest non-cytotoxic conc. in HEK293 | Highest non-cytotoxic conc. in mESCn | Concentration for hit finding in NCC | LOAEC in NCC |
|----------|---------|----------------|------------|----------------------------------------|--------------------------------------|--------------------------------------|--------------|
| Terflunomide | DMSO | 10.8 µM | 54.0 nM | 120.0 µM | 3.5 µM | 1 µM |
| Nintedanib/BIBF 1120 | DMSO | 74.2 nM | 70.6 nM | 42.8 nM | 2.0 nM | 100 µM |
| Telaprevir | DMSO | 5.1 µM | 1.6 µM | 21.1 µM | 10.0 µM | 10 µM |
| Sitagliptin | DMSO | 1.9 µM | 1.2 µM | 100.0 µM | > 50.0 µM | 100 µM |
| Atripirone | DMSO | 647.3 nM | 7.8 nM | 2.0 µM | 970.0 nM | 2 µM | 102 nM |
| Rosflumilast | DMSO | 18.0 nM | 0.2 nM | 10.0 µM | > 50.0 µM | 10 µM |
| Exenatide | DMSO | 44.7 nM | 0.3 nM | 50.0 nM | > 20.0 nM | 50 nM |
| Gefitinib/Iressa | DMSO | 1.2 µM | 34.0 nM | 24.4 µM | 500.0 nM | 500 nM |
| Rivaroxaban | DMSO | 699.6 nM | 41.4 nM | 10.0 µM | > 10.0 µM | 1 µM |
| Aliskiren | DMSO | 326.5 nM | 166.0 nM | 100.0 µM | 5.0 µM | 50 µM |
| Galrin | DMSO | n.a. | n.a. | n.t. | > 3.0 nM | 3 nM |
| Neuregulin | 0.1% BSA | 6.3 µM | n.a. | n.t. | > 3.0 nM | 3 nM |
| Erythropoietin | 0.1% BSA | 0.3 nM | n.a. | n.t. | > 0.3 nM | 3 nM |
| Geldanamycin | DMSO | 0.8 µM | 0.5 µM | 44.0 nM | 8.0 nM | 16 nM | 5 nM |
| G-CSF | 0.1% BSA | 1.3 µM | n.a. | n.t. | > 2.7 nM | 10 nM |
| IFNβ | 0.1% BSA | 0.4 µM | 7.5 nM | 0.4 µM | 7.5 nM | n.t. | > 200.0 µM | 500 µM | 36 µM |
| Sildenafil | DMSO | 221.0 nM | 11.0 nM | 50.0 µM | > 50.0 µM | 50 µM |
| Imatinib | DMSO | 3.0 µM | 224.0 nM | 10.0 µM | 7.0 µM | 5 µM | 2 µM |
| Oxytocin | 0.1% BSA | 2.0 nM | 2.0 nM | > 100.0 nM | > 100.0 µM | 100 nM |
| Sulfadiazine | DMSO | 320.0 nM | 160.0 nM | 100.0 µM | > 50.0 µM | 50 nM |
| Amiodarone | DMSO | 2.3 µM | 0.5 nM | 10.0 µM | 400.0 nM | 10 µM |
| Chlorpromazine | DMSO | 332.0 nM | 58.9 nM | 50.0 µM | 340.0 µM | 1 µM |
| Methoxyacetic acid | 0.1% NaHCO₃ | See background data in supplemental material (Fig. S4) | 128.0 µM | > 50.0 µM | 50 µM |
| Cyproconazole | DMSO | 100.0 µM | > 50.0 µM | 5 µM | 2 µM |
| Triadimefon | DMSO | 50.0 µM | > 50.0 µM | 50 µM | 46 µM |
| PCB-153 | DMSO | 25.0 µM | 10.0 µM | 5 µM | 787 nM |
| PBDE-99 | DMSO | 20.0 µM | 5 µM | 20 µM | 4 µM |
| Arsenic trioxide | 0.1% NaHCO₃ | 0.7 µM | 0.6 µM | 25.0 nM | 500 pM | 1 µM | 378 nM |

---

**Fig. 3** Toxicological background data for all compounds screened in the test battery. The solvent used for each compound is indicated. Data on clinical concentrations (maximal plasma concentration) and the free plasma concentrations are explained in greater detail in supplementary Fig. S4. The data obtained from the cytotoxicity pre-screening in HEK293 and mEScn cells are reported as the real data points closest to the mathematically modeled highest non-cytotoxic concentrations (BMCL15). The highest non-cytotoxic concentration determined in the UKn2 test system is also indicated. The last column indicates the lowest observed adverse effect concentration (LOAEC), the concentration triggering a 20% inhibition of migration of the neural crest cells. (n.a. not available data, n.t. not tested)
cytoskeleton and thereby to affect the cellular migration capacity. Vice versa, an environmental toxicant that inhibits a cellular pathway may need to do this continuously to exert developmental effects, i.e., an average toxic concentration (AUC) needs to be maintained to result in an average long-term inhibition. A short pulse, even at $C_{\text{max}}$ may not be toxic. However, the situation would be different, if the compound (such as arsenite) binds irreversibly to cellular structures above a certain threshold concentration. Under such circumstances, the $C_{\text{max}}$ values would become relevant.

Inhibition of neural crest cell migration by test battery library

As first assay to be run within the framework of the test battery, we chose the UKn2 test system that evaluates interference of potential toxicants with neural crest (NC) cell migration (Zimmer et al. 2012). For the primary screen, the library was run at a single concentration, selected according to the cytotoxicity pre-screening. At this concentration the viability of NCC was determined. If the concentration was non-toxic for NCC, then inhibition of migration was determined in the mInC assay. If the compounds were initially toxic, the UKN2 toxicity threshold was determined and then the MINC assay was performed at this concentration. When comparing cytotoxicity tests across different cell lines and models, we observed that cytotoxicity depends not only on the cell type and the medium used. Often minor experimental details affected the outcome (e.g., the plate type used). Therefore, the most relevant cell viability data were obtained when this endpoint was measured in each test run, and directly within the sample used for measuring the specific endpoint (e.g., migration). For instance, about two-thirds of the test compounds showed similar cytotoxicity thresholds in the pretesting models (HEK293; mesCn) and the MINC. For two compounds, cytotoxicity of the NCC resembled rather the mESC than HEK293; for three other compounds, NCC sensitivity was closer to that of HEK293. After identification of adequate concentrations viability and MINC data were obtained for each compound, and experiments were repeated at this test concentration with two further cell preparations (Figs. 5, 6). Hit compounds (Fig. 5) reduced the migration for at least 25 %, while they reduced cell viability in the same assay for <10 %. Non-hits did either not affect migration strongly, or they influenced migration only above the cytotoxicity threshold (Fig. 6). Altogether 11 hits were identified, 5 of which came from the group of drugs. Within the latter group, the hit rate was 23 %; among the environmental compounds, the hit rate was 100 %.

Determination of the minimal concentration triggering developmental toxicity

To follow up on the hits from the initial screen by the MINC assay, a broader range of concentrations of these...
Fig. 5 Overview of hits identified in the UKn2 test system. Neural crest cells were exposed to the highest non-cytotoxic concentration of test compounds for 48 h. The inhibition of cell migration and cytotoxicity induced by different compounds were measured by a the MINC and b resazurin assays. Substances leading to ≥25 % reduction in the NCC migration activity in the presence of ≤10 % cytotoxicity (compared with the untreated controls) were considered UKn2-positive hits. Data are mean ± SD of three independent experiments normalized to untreated controls. *p < 0.05, **p < 0.01, ***p < 0.001.

Fig. 6 Overview of negative compounds in the UKn2 test system. The results of a 48 h exposure of neural crest cells to the highest non-cytotoxic concentration of test compounds are shown. The inhibition of cell migration and cytotoxicity induced by different compounds were measured by a the MINC and b resazurin assays. Substances showing reduction in cell viability (>10 %) and/or reduction in migration <25 % (compared with the control) were considered UKn2-negative compounds. Data are mean ± SD of three independent experiments normalized to untreated controls. *p < 0.05, **p < 0.01, ***p < 0.001.
compounds was tested in the same assay. We used these data to determine the lowest concentration inhibiting the specific test endpoint—neural crest cell migration. A non-linear regression was fitted to the concentration–effect curve (Figs. 7, 8). For this type of follow-up assay, we assumed that a reduction in migration by 20 % was of biological and toxicological significance. The concentration triggering this extent of inhibition was determined and defined here as the ‘lowest observed adverse effect concentration’ (LOAEC). This value represents the lowest concentration at which inhibition of migration would become toxicologically relevant in our test system (Fig. 3).

Examples of PBPK modeling for hit compounds to relate in vitro correlations to realistic exposure scenarios

We selected three compounds for more detailed comparisons of LOAEC values and toxicologically relevant in vivo concentrations. First, recombinant human IFN-β was examined. A PBPK model for the analysis of IFN-β kinetics in monkeys has been described by Mager et al. (2003). In this study, IFN-β plasma concentrations were measured during a period of 48 h in order to determine the pharmacokinetic and pharmacodynamic parameters necessary for modeling. The model of Mager et al. (2003) postulates a decrease in receptor density upon repeated exposure to IFN-β, and an elimination of IFN-β (internalized into cells) depending on the receptor density. We implemented this PK model in the acslX software, and we simulated the kinetics of IFN-β after exposure to a dose known to trigger developmental toxicity in animals: this simulated toxic dose was chosen based on an unpublished report summarized by the US FDA (see materials and methods). In this report, developmental toxicity in pregnant monkeys exposed to IFN-β was shown for a dose of 740 ng/kg/day (=33 pmol/kg/day, assuming a molecular weight of 22.5 kDa) given from gestational day 90 to term (GD160). Our simulations showed for a subcutaneous dose of 33 pmol IFN-β/kg/day that receptor density decreased by about one-third. As a consequence, daily average plasma concentrations of IFN-β
increased from 0.9 to 1.5 pm. The simulated plasma peak concentrations were in the range of 2–3 pm (Fig. 8e). This value was about tenfold lower than our in vitro NOAEL (no observed adverse effects level), i.e., still within the same order of magnitude.

Triadimefon was the second compound selected for PK modeling because it represents a specific nCC toxicant (Zimmer et al. 2012; Menegola et al. 2005). Further knowledge on the mechanisms of toxicity would be of high interest. We revisited/reconstructed the PBPK model by Crowell et al. (2011) to predict the target tissue concentrations related to the exposure scenarios leading to published toxic effects on male fertility and the CNS (Goetz et al. 2007; Crofton et al. 2011), i.e., a dose of 50 mg/kg triadimefon. The maximum simulated total in vivo concentration (C_{max}) and its average in the 24-h period (C_{24h}) in plasma and brain were used as relevant exposure metrics. Equal contribution of triadimefon and its metabolite triadimenol to the observed effects relative to their concentrations was assumed; therefore, the concentrations of both compounds were added. The obtained in vivo total concentration values were used in order to assess the equivalent in vitro concentrations (Fig. 9a). We simulated two scenarios: dietary exposure assuming a constant intake of the entire drug dose within the first 12 h of a 24-h period (Fig. 9b,c); oral gavage, modeled as a bolus dose into the liver compartment (Fig. 9d,e). The averaged C_{24h} simulated in vivo in plasma after dietary exposure was estimated to be 18 μM, with a C_{max} of 32 μM. C_{24h} and C_{max} in CSF were accordingly 15 and 27 μM. Based on the parameters listed in Fig. 9a and on the equations reported in Materials and Methods, we calculated the free concentration in vivo and the equivalent total concentration in vitro (about 1 μM in plasma, and 18–33 μM in CSF) (Fig. 9b). The same approach was used for the second analyzed scenario. A single dose of 50 mg/kg of triadimefon administrated by gavage was simulated in our model. The equivalent in vitro concentrations were 17–196 μM (Fig. 9d). This illustrates that in vivo plasma concentrations were within the range of the MINC NOAEL.
The third compound studied was PBDE-99. A new PBPK model was established for this purpose (Fig. S3). It was used to simulate concentrations in the rapid equilibrium compartment (e.g., plasma) corresponding to the lowest exposures related to neurodevelopmental toxicity described in Kuriyama et al. (2005) and Viberg et al. (2005). An oral dose of 0.11 μmol/kg (on gestational day 6, as used in the first study) was simulated to lead to a maximum concentration of 0.1 μM in our model (Fig. S5a). An oral dose of 1.4 μmol/kg (on postnatal day 10,
as used by Viberg et al. (2005) led to a simulated maximum concentration of 1.3 μM, with an average concentration of 0.82 μM over the first 10 days after exposure (Fig. S5a). These concentrations were within the same order of magnitude as the MINC NOAEL.

Discussion

In the present study, we defined the framework for an in vitro developmental toxicity test battery. Although it was originally designed for assay systems that have been developed by the ESNATS consortium (Leist et al. 2013), it may be expanded by any other robust test. Additionally, we performed a feasibility study. For this, we chose the MINC assay (Zimmer et al. 2012), because its throughput and its functional endpoint allowed us to judge the suitability of the test strategy and compound library within a reasonable time frame. The environmental chemicals with known DNT hazard potential that were included into the screen were all identified as hits. This confirmed the very high sensitivity of the assay. More importantly, new hits were identified among the group of medical drugs. This points to the usefulness of the test battery to provide safety information on hitherto non-characterized drugs or environmental compounds.

The field of developmental neurotoxicity relies on only a handful of generally accepted positive controls, such as mercury, lead and pesticides (Grandjean and Landrigan 2006; Kuegler et al. 2010; Kadereit et al. 2012). This situation is due to a lack of comprehensive human epidemiological data as well as a dearth of DNT guideline studies on animals (Rovida et al. 2011; Makris et al. 2009; van Thriel et al. 2012). Therefore, instead of solely relying on the compounds that have been used in the past, we applied a new approach by combining well-known positive controls with new compounds mainly belonging to the group of medical drugs. The test battery approach gives the opportunity to qualify this new group of compounds by non-tiered testing in multiple assays covering different key biological processes. We envisage that this approach will yield some extremely well-characterized drug compounds, which could then be used in the future to increase the list of positive controls for in vitro assays. Moreover, performance of the assays would be characterized by their hit patterns and by mechanistic studies on the hits in the respective test systems.

Although we acknowledge that our approach has weaknesses concerning the definition of positive controls, it provides nevertheless a new opportunity for breaking a vicious circle between lack of sufficient reference compounds and a paucity of validated assays. We feel that this strategy is worth being explored considering also that this approach has been successful in other fields. For instance, the area of chemically induced carcinogenesis faces similar problems, despite more than 1,000 times larger research efforts. The list of IARC (International Agency for Research on Cancer) group 1 compounds (define human carcinogens) contains only about four dozen chemicals. Considering the heterogeneity of cancer, this number is far too low to validate any assay by conventional correlative statistics. Nevertheless, many assays have been developed, and many chemicals have been classified as potential carcinogens. This was done by recurrent optimization cycles involving testing of compounds, assay optimization, and adaptation of interpretation models. Human data are hard to obtain for chemically induced carcinogenesis, but some key biological processes responsible for human carcinogenesis, such as mutagenesis, promotion of growth, loss of contact inhibition can be defined and tested individually in vitro (Adler et al. 2011). This procedure and experience may be transferred to the field of DNT. We therefore believe that increasing the size and heterogeneity of the test compound library as well as comparing the toxicity data obtained in several assays for key biological processes will be a successful strategy to overcome the lack of positive controls for DNT/DT.

By adding the new group of medical drugs to the test battery library, we also addressed a further issue: applicability domains of most existing assays are poorly defined. The currently available test systems have been characterized by the use of well-known positive control compounds, which mainly belong to the group of environmental toxicants (Klaric et al. 2013; Vojnits et al. 2012; Krug et al. 2013a; Pallaisca et al. 2013; Laurenza et al. 2013; Piersma et al. 2013; Bal-Price et al. 2012; Crofton et al. 2011; Coecke et al. 2007; Lein et al. 2007; Kadereit et al. 2012). Some others have used at most one to three drug-like compounds (Balmer et al. 2012; Stiegler et al. 2011; Kuegler et al. 2012; Meganathan et al. 2012; Jagtap et al. 2011; Falsig et al. 2004). Therefore, it is not clear whether these test systems are able to predict DT of drugs or specific groups of environmental compounds. Apart from two screening assays developed in the context of ESNATS (Kern et al. 2013; Krug et al. 2013a) the published assays have never been challenged by a broad range of drugs, and they may therefore not have been optimized to detect their adverse effects. However, the pharmaceutical industry would need such new assays capable to predict human DT in a more reliable fashion than the currently available tests. In the past years, pharmaceutical companies have struggled more and more to develop new drugs, while at the same time drugs already on the market had to be withdrawn due to safety issues. Between 1999 and 2011, 19 % of 279 newly approved drugs in Europe were reported to have post-approval safety issues and five drugs had to be withdrawn from the market (Mol et al. 2013).
The strategy used here also attempts to provide a new perspective on how the field of in vitro DT testing may advance with regards to future validation of assay systems. The classical situation foresees the comparison of in vitro toxic concentrations with the known in vivo toxic doses, as major indication of biological relevance. This approach is not suitable for developmental toxicity testing since not enough animal data are available. As alternative, a mechanistic validation has been proposed (Leist et al. 2008b, 2012b; Hartung et al. 2013). This concept is based on the assumption that toxicants disrupt key biological processes, and that test systems identify compounds that disrupt such processes (Leist et al. 2010; Crofton et al. 2011; Kadereit et al. 2012). For instance, cell migration represents such a key process (Fritsche et al. 2011; Moors et al. 2009), and inhibition of precursor cell migration in the nervous system may lead to persistent and externally visible DT. If a DNT assay is designed to identify such effects, its validity estimate would increase, as soon as it can be shown that the test is based on cell biological and signaling processes controlling precursor cell migration. Validity would increase even more, if it can be demonstrated that compounds interfering with such processes are identified as hits in the test system. Furthermore, it would be important for mechanistic validation to demonstrate that chemicals score as hits because they interrupt such defined processes, and that toxicity may be rescued by a defined, mechanistically understood counter-regulation (Krug et al. 2013a; Zimmer et al. 2011b; Pöltl et al. 2012; Wang et al. 2007; Volbracht et al. 1999; Wayman et al. 2012a, b; Schildknecht et al. 2013). The evaluation of such a test system would thereby be independent of classical positive controls; it would solely be based on knowledge regarding toxicity pathways. Our test battery framework would allow such approaches under the following conditions: first, the same compounds will be tested in different, mechanistically defined test systems; by evaluating different endpoints and comparing the data obtained from different assays, more information will be gained on the general mode of action of those toxicants. The testing strategy needs to reach beyond the primary screening of toxicants to document adverse effects; additional mechanistic characterization in secondary assays and whole-genome transcriptomics analysis of hits is an essential part of the strategy. This should promote our understanding of the pathways mainly affected by the exposure to the toxicants and of the pathways responsible for the toxicity.

Apart from the compound selection, we took a second unconventional approach with respect to the choice of compound test concentrations. In drug discovery, it has been general practice to screen compounds at fixed absolute concentrations. In contrast to this, we used relative concentrations. Biological activity of the compounds in vitro and in vivo, e.g., cytotoxicity, and clinical plasma concentrations were included as reference. Testing was performed relative to such reference concentrations. In most cases, the non-cytotoxic range was evaluated and chosen as starting point for the screen. However, depending on the compounds, other criteria have been considered as more appropriate; this has been the case for cytokines that were tested in concentration ranges corresponding to the levels expected in body fluids during clinical application. This strategy was designed for test systems whose throughput is limited to some extent. For assays with very high throughput, an alternative approach would be to simply screen a large number of concentrations over the entire range of compound solubility. This approach is taken for instance by the national toxicology program of the USA (Xia et al. 2008; Attene-Ramos et al. 2013; Tice et al. 2013) or the EPA ToxCast program (Judson et al. 2010; Sipes et al. 2013).

The current data are only derived from a first screening step. In the future one could imagine linking the functional disturbance of substances found in the MINC with more mechanistic data obtained in the assay itself, but also in other tests within the framework. This would allow to deepen our understanding of possible pathways of toxicity. Using the MINC assay in the first initial screen allowed us to identify 23% of compounds belonging to the drug group as potential DNT/DT toxicants. On the other hand, more than 70% of the drugs in our library did not show any specific effect, although they have potent biological activity in many other tests. This suggests that the MINC assay does not react entirely specifically to any drug-like compound or biologic.

Among the newly identified hits, we found three anticancer drugs (abiraterone, geldanamycin and imatinib), an anti-psychotic drug (chlorpromazine) and a cytokine, mostly used for multiple sclerosis treatment (IFN-β). Abiraterone and imatinib have been shown to promote remission of different metastatic cancers (Patel 2013). Possibly, such findings are related to an inhibition of migration of cancer cells as well, and this may be tested in the future. Also in the case of the HSP90 inhibitor geldanamycin, other studies agree with our findings in the MINC assay. The effect of the drug on cell migration has been studied in several cancer cell lines. Activity of focal adhesion kinases, actin reorganization and integrin activation was inhibited by geldanamycin in bladder carcinoma cells (Koga et al. 2007). Furthermore, chemotactic activity in sarcoma cells (Lesko et al. 2007) as well as migration of glioma cells was reduced (Zagzag et al. 2003). Also the dopamine antagonist chlorpromazine, has been shown by other studies to inhibit migration in a pancreatic carcinoma cell line, via inhibition of k-RAS (Eisenberg et al. 2008).

Interference of IFN-β with migration has also been shown in several in vitro studies; the cytokine seems to modulate the activity of chemokine receptors and matrix remodeling proteases (e.g., CCR7, MMP9) in dendritic and
immune cells (Yen et al. 2010; Stuve et al. 1996). So far, these mechanistic findings have not been corroborated in an in vivo setting, but the drug showed potential DNT activity in in vivo studies (US FDA, see Materials and Methods). Modeling the pharmacokinetics of the drug, we found that the toxic effect is triggered by a blood concentration of 1.9–3 pM. About 100-fold higher concentrations may be reached upon bolus injections (i.v.) (Yung et al. 1991), and the LOAEC observed in the MINC assay is about in the middle of this concentration range. The molecular targets responsible for the adverse effect of IFN-β seen in those and in our study are not known. We hope that further characterization of the compound in the MINC assay and other assays of the battery will provide more details regarding the mode of action relevant for toxicity.

For the future, we suggest that the compound library may be expanded, and data from different publications and laboratories may be stored in a common database. It cannot be stressed enough that initial hit-finding is only the first step of this strategy. Complementary information from multiple assays, pharmacokinetic modeling and mechanistic follow-up studies are necessary components of the overall framework. For instance, transcriptome data and measurement of other Omics and functional endpoints (Bouhifd et al. 2013; Hogberg et al. 2011; Ramirez et al. 2013; Lefew et al. 2013) will expand our knowledge regarding the toxicity mechanisms of chemicals. Moreover, such data will serve as a knowledge base concerning the biological processes and signaling pathways that need to be covered by a future DNT test battery. This will help us to identify redundancies, complementarities, strengths, weaknesses, applicability domains and limitations of current individual assays with regards to their predictive value for DNT.

Acknowledgments We are grateful to Ms H. Leisner and M. Kapitza for invaluable experimental support. We are indebted to Drs N. Balmer, J. Hescheler and many other colleagues for valuable contributions and insightful discussions during the course of this work. This work was supported by Grants and support from the German research foundation (research training group 1331), the Land-BW and the European Community’s ESNATS project.

Conflict of interest The authors declare no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V et al (2011) Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch Toxicol 85(5):367–485. doi:10.1007/s00204-011-0693-2

Attene-Ramos MS, Huang R, Sakamura S, Witt KL, Beeson GC, Shou L et al (2013) Systematic study of mitochondrial toxicity of environmental chemicals using quantitative high throughput screening. Chem Res Toxicol 26(9):1323–1332. doi:10.1021/tr4001754

Balmer NV, Weng MK, Zimmer B, Ivanova VN, Chambers SM, Nikolaeva E et al (2012) Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. Human Mol Genet 21(18):4104–4114. doi:10.1038/hmg/ddx239

Bal-Price AK, Coecke S, Costa L, Crofton KM, Fritsche E, Goldberg A et al (2012) Advancing the science of developmental neurotoxicity (DNT): testing for better safety evaluation. Altex 29(2):202–215

Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, Loonam K et al (2003) Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in Parkinsonian mice. Nat Biotechnol 21(10):1200–1207. doi:10.1038/nbt870

Basketter DA, Clewell H, Kimber I, Rossi A, Blaauboer B, Burrier R et al (2012) A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing—t4 report*. Altex 29(1):3–91

Bosgra S, van Eijkeren J, Bos P, Zeilmaker M, Slob W (2012) An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit Rev Toxicol 42(9):751–767. doi:10.3109/10408444.2012.709225

Bouhifd M, Hartung T, Hogberg HT, Kleensang A, Zhao L (2013) Review: toxicometabolomics. J Appl Toxicol JAT 33(12):1365–1383. doi:10.1002/jat.2874

Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Belilies RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407–484

Chen LJ, Lebetkin EH, Sanders JM, Burka LT (2006) Metabolism and disposition of 2,2′,4,4′,5-pentabromodiphenyl ether (BDE99) following a single or repeated administration to rats or mice. Xenobiotica 36(6):515–534. doi:10.1080/00958900600674477

Coecke S, Goldberg AM, Allen S, Buzanska L, Calamandrei G, Crofton K et al (2007) Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Environ Health Perspect 115(6):924–931. doi:10.1289/ehp.9427

Crofton KM, Mundy WR, Lein PJ, Bal-Price A, Coecke S, Seiler AE et al (2011) Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals. Altex 28(1):9–15

Crowell SR, Henderson WM, Kenneke JF, Fisher JW (2011) Development and application of a physiologically based pharmacokinetic model for triadimefon and its metabolite triadimenol in rats and humans. Toxicol Lett 205(2):154–162. doi:10.1016/j.toxlet.2011.05.1036

Di Renzo F, Broccia ML, Giavini E, Menegola E (2007) Antifungal triazole derivative triadimefon induces ectopic maxillary cartilage by altering the morphogenesis of the first branchial arch. Birth Defects Res Part BDev Reprod Toxicol 80(1):2–11. doi:10.1002/jat.1658

Eisenberg S, Giehl K, Hensl Y, Ehrlich M (2008) Differential interference of chlorpromazine with the membrane interactions of oncogenic K-Ras and its effects on cell growth. J Biol Chem 283(40):27279–27288. doi:10.1074/jbc.M803589200

Falsig J, Latta M, Leist M (2004) Defined inflammatory states in astrocyte cultures: correlation with susceptibility towards CD95-driven apoptosis. J Neurochem 88(1):181–193

Fritsche E, Gassmann K, Schreiber T (2011) Neurospheres as a model for developing alternative methods for the screening and prioritization of chemicals. Altex 28(3):175–181. doi:10.1002/jat.2011.05.1036
Koga F, Tsutsumi S, Neckers LM (2007) Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle 6(11):1393–1402

Krug AK, Balmer NV, Matt F, Schonenberger F, Merhof D, Leist M (2013a) Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. doi:10.1007/s00204-013-1072-y

Krug AK, Kolde R, Gaspar JA, Rempel E, Balmer NV, Meganathan K et al (2013b) Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol 87(1):123–143. doi:10.1007/s00204-012-1067-3

Kugeler PB, Zimmer B, Waldmann T, Bauldis B, Ilmjarv S, Hescheler J et al (2010) Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing. Altx 27(1):17–42.

Kugeler PB, Baumann BA, Zimmer B, Keller S, Marx A, Kadereit S et al (2012) GFAP-independent inflammatory competence and trophic functions of astrocytes generated from murine embryonic stem cells. Glia 60(2):218–228. doi:10.1002/glia.21257

Kuriyama SN, Talsness CE, Grote K, Chahoud I (2005) Developmental exposure to low dose PBDE 99: effects on male fertility and neurobehavior in rat offspring. Environ Health Perspect 113(2):149–154

Laurenza I, Pallocca G, Menecceozzi M, Scello B, Pammies D, Bal-Price A (2013) A human pluripotent carcinoma stem cell-based model for in vitro developmental neurotoxicity testing: effects of methylmercury, lead and aluminum evaluated by gene expression studies. Int J Dev Neurosci Off J Int Soc Dev Neurosc. doi:10.1016/j.jdevneu.2013.03.002

Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA et al (2009) Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461(7262):402–406. doi:10.1038/nature08320

Lefew WR, McConnell ER, Crooks JL, Shafer TJ (2013) Evaluation of microelectrode array data using Bayesian modeling as an approach to screening and prioritization for neurotoxicity testing. Neurotoxicology 36:34–41. doi:10.1016/j.neurotox.2013.02.006

Lein P, Locke P, Goldberg A (2007) Meeting report: alternatives for developmental neurotoxicity testing. Environ Health Perspect 115(5):764–768. doi:10.1289/ehp.9841

Leist M, Bremer S, Brundin P, Hescheler J, Kirkeby A, Krause KH et al (2008a) The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy. Altx 25(3):163–190

Leist M, Hartung T, Nicotera P (2008b) The dawnning of a new age of toxicology. Altx 25(2):103–114

Leist M, Efremova L, Karreman C (2010) Food for thought... considerations and guidelines for basic test method descriptions in toxicology. Altx 27(4):309–317

Leist M, Hasiwa N, Daneshian M, Hartung T (2012a) Validation and quality control of replacement alternatives—current status and future challenges. Toxicol Res 1:8

Leist M, Lidiary BA, Yang C, Hayden PJ, Kelm JM, Ringeisser S et al (2012b) Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. Altx 29(4):373–388

Leist M, Ringwald A, Kolde R, Bremer S, van Thriel C, Krause KH et al (2013) Test systems of developmental toxicity: state-of-the-art and future perspectives. Arch Toxic 87(12):2037–2042. doi:10.1007/s00204-013-1154-x

Lesko E, Godzijek I, Kijowski J, Jennen B, Wiecha O, Majka M (2007) HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs 18(10):1173–1181. doi:10.1097/CAD.0b013e3282e5f32d
Mager DE, Neuteboom B, Ethymiopoulos C, Munafò A, Jusko WJ (2003) Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther 306(1):262–270. doi:10.1124/jpet.103.049502

Makris SL, Raffaele K, Allen S, Bowers WJ, Hass U, Alleva E et al (2009) A retrospective performance assessment of the developmental neurotoxicity study in support of OECD test guideline 426. Environ Health Perspect 117(1):17–25. doi:10.1289/ehp.11447

Meganathan K, Jagtap S, Wagh V, Winkler J, Gaspar JA, Hildebrand D et al (2012) Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells. PLoS ONE 7(8):e44228. doi:10.1371/journal.pone.0044228

Menegola E, Broccia ML, Di Renzo F, Prati M, Giavini E (2000) In vitro teratogenic potential of two antifungal triazoles: triadimefon and triadimenol. In Vitro Cell Dev Biol Anim 36(2):88–95. doi:10.1290/1071-2690(2000)036<0088:IPTATF>2.0.CO;2

Menegola E, Broccia ML, Di Renzo F, Massa V, Giavini E (2005) Craniofacial and axial skeletal defects induced by the fungicide triadimefon in the mouse. Birth Defects Res Part B Dev Reprod Toxicol 74(2):185–195. doi:10.1002/bdrb.20035

Mol PG, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG, Menegola E, Broccia ML, Di Renzo F, Massa V, Giavini E (2005) Craniofacial and axial skeletal defects induced by the fungicide triadimefon in the mouse. Birth Defects Res Part B Dev Reprod Toxicol 74(2):185–195. doi:10.1002/bdrb.20035

Mol PG, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG, Haaijer-Ruskamp FM et al (2013) Post-approval safety issues with innovative drugs: a European cohort study. Drug Saf Int J Med Toxicol Drug Exp 36(11):1105–1115. doi:10.1007/s00280-013-0122-2

Moors M, Rockel TD, Abel J, Cline JE, Gassmann K, Schreiber T et al (2013) Human neurospheres as three-dimensional cellular systems for developmental neurotoxicity testing. Environ Health Perspect 117(11):1131–1138

Padilla S, Corum D, Padnos B, Hunter DL, Beam A, Houck KA et al (2012) Zebrafish developmental screening of the ToxCast Phase I chemical library. Reprod Toxicol 33(2):174–187. doi:10.1016/j.reprotox.2011.10.018

Pallocca G, Fabbri M, Sacco MG, Gribaldo L, Pamies D, Laurenza I et al (2013) miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol 29(4):239–257. doi:10.1007/s10565-013-9250-5

Patel S (2013) Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol 72(2):277–286. doi:10.1007/s00280-013-2135-8

Piersie AH, Bosgra S, van Duursen MB, Hermens SA, Jonker L.R, Kroese et al (2013) Evaluation of an alternative in vitro test battery for detecting reproductive toxicants. Reprod Toxicol 33(2):174–187. doi:10.1016/j.reprotox.2010.05.012

Politi D, Schildknecht S, Karremen C, Leist M (2012) Uncoupling of ATP-depletion and cell death in human dopaminergic neurons. Neurotoxicology 33(4):769–779. doi:10.1016/j.neuro.2011.12.007

Preynat-Seauve O, Suter DM, Tirefert D, Turchind R, Viroille T, Chneiwers NS, Martin MT, Reif DM, Kleinsteuerc NC, Judson RS, Singh AV et al (2011) Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol Sci Off J Soc Toxicol 124(1):109–127. doi:10.1093/toxsci/kfr220

Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM et al (2013) Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol 26(6):787–895. doi:10.1021/tr40021f

Stieger LV, Krug AK, Matt F, Leist M (2011) Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures. Toxicol Sci Off J Soc Toxicol 121(1):73–87. doi:10.1093/toxsci/kfr034

Stummann TC, Hareng L, Bremer S (2009) Hazard assessment of methylmercury toxicity to neuronal induction in embryogenesis using human embryonic stem cells. Toxicology 257(3):117–126. doi:10.1016/j.tox.2008.12.018

Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G et al (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40(6):853–863. doi:10.1002/ana.410400607

Suzuki N, Ando S, Sumida K, Horie N, Saito K (2011) Analysis of altered gene expression specific to embryotoxic chemical treatment during embryonic stem cell differentiation into myocardial and neural cells. J Toxicol Sci 36(5):569–585

Takahashi K, Tanabe K, Ohnuki M, Naita M, Ichisaka T, Tomoda K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872. doi:10.1016/j.cell.2007.11.019

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waksman MA, Swiergiel JJ, Marshall VS et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147

Tice RR, Austin CP, Kavlock RJ, Bucher JR (2013) Improving the human hazard characterization of chemicals: a Tox21 update. Environ Health Perspect 121(7):756–765. doi:10.1289/ehp.1205784

Us EPA (2006) Re-registration eligibility decision for triadimenol and triadimenol and tolerance reassessment for triadimenol. Office of Pesticide Programs, United States Environmental Protection Agency, Washington D.C

van Thriel C, Westerink RH, Beste C, Bale AS, Lein PJ, Leist M (2013) Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts. Neurotoxicology 34(4):911–924. doi:10.1016/j.neuro.2011.10.002

Viberg H, Fredriksson A, Eriksson P (2005) Deranged spontaneous behaviour and decrease in cholinergic muscarinic receptors in hippocampus in the adult rat, after neonatal exposure to the brominated flame-retardant, 2,2′,4,4′,5-pentabromodiphenyl ether (PBDE 99). Environ Toxicol Pharmacol 20(2):283–288. doi:10.1016/j.etap.2005.02.004

Vojnits K, Ensenat-Waser K, Gaspar JA, Meganathan K, Jagtap S, Herschler J et al (2012) A transcriptomics study to elucidate the toxicological mechanism of methylmercury chloride in a human stem cell based in vitro test. Curr Med Chem 19(36):6224–6232

Voitl C, Leist M, Nicotera P (1999) ATP controls neuronal apoptosis triggered by microtubule breakdown or potassium deprivation. Mol Med 5(7):477–489

Schildknecht S, Karrremen C, Politi D, Efremova L, Kullmann C, Gubier S et al (2013) Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. Altex 30(4):427–444

Seiler AE, Spielmann H (2011) The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat Protoc 6(7):961–978. doi:10.1038/nprot.2011.348

Sipes NS, Martin MT, Kleinsteuerc NC, Judson RS, Singh AV et al (2011) Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol Sci Off J Soc Toxicol 121(1):109–127. doi:10.1093/toxsci/kfr220
Wang L, Zhang ZG, Gregg SR, Zhang RL, Jiao Z, LeTourneau Y et al. (2007) The Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem 282(44):32462–32470. doi:10.1074/jbc.M706880200

Wayman GA, Bose DD, Yang D, Lesiak A, Bruun D, Impey S et al. (2012a) PCB-95 modulates the calcium-dependent signaling pathway responsible for activity-dependent dendritic growth. Environ Health Perspect 120(7):1003–1009. doi:10.1289/ehp.1104833

Wayman GA, Yang D, Bose DD, Lesiak A, Ledoux V, Bruun D et al. (2012b) PCB-95 promotes dendritic growth via ryanodine receptor-dependent mechanisms. Environ Health Perspect 120(7):997–1002. doi:10.1289/ehp.1104832

Xia M, Huang R, Witt KL, Southall N, Fostel J, Cho MH et al. (2008) Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect 116(3):284–291. doi:10.1289/ehp.10727

Yen JH, Kong W, Ganea D (2010) IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. J Immunol 184(7):3478–3486. doi:10.4049/jimmunol.0902542

Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS et al. (1991) Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol Off J Am Soc Clin Oncol 9(11):1945–1949

Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N et al. (2003) Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196(2):394–402. doi:10.1002/jcp.10306

Zimmer B, Kuegler PB, Baudis B, Genewsky A, Tanavde V, Koh W et al. (2011a) Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. Cell Death Differ 18(3):383–395. doi:10.1038/cdd.2010.109

Zimmer B, Schildknecht S, Kuegler PB, Tanavde V, Kadereit S, Leist M (2011b) Sensitivity of dopaminergic neuron differentiation from stem cells to chronic low-dose methylmercury exposure. Toxicol Sci Off J Soc Toxicol 121(2):357–367. doi:10.1093/toxsci/kfr054

Zimmer B, Lee G, Balmer NV, Meganathan K, Sachinidis A, Studer L et al. (2012) Evaluation of developmental toxicants and signaling pathways in a functional test based on the migration of human neural crest cells. Environ Health Perspect 120(8):1116–1122. doi:10.1289/ehp.1104489

 Springer